Predicting Progression in Barrett's Esophagus: Is the Holy Grail Within Reach?
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 32287139.
- Also identified by DOI 10.14309/ajg.0000000000000635 and PMC identifier 7274875.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Risk stratification in Barrett's esophagus may allow aggressive management of those at "high risk" and reduction in surveillance in at "low" risk. Davison et al. report the results of the independent validation of a multibiomarker panel (TissueCypher assay) performed on biopsy tissue, in a case control study. "High-risk" patients progressed 5 times more than those at "low risk." Sensitivity and specificity for "high-risk" patients were 29% and 86% with a positive predictive value of 23%. A negative predictive value of a "low-risk" score was 96%. These findings may allow more intensive surveillance in those at "high risk." Despite some limitations, this assay is a potentially major advance in the management of Barrett's esophagus patients without dysplasia.
Medical subject headings
- Barrett Esophagus
- Esophageal Neoplasms